Document is current
Any future updates will be listed below
-
Authors
Khosropour, Christine M.
Riley, Taylor
Healy, Elise
Backus, Kandis V.
Gomillia, Courtney E.
Mena, Leandro
Lockwood, Khadijra R.
Gordon, Felicia M.
Means, Arianna R.
Ward, Lori M.
- License Information
-
More Information
Article History
Received: 7 October 2022
Accepted: 7 June 2023
First Online: 13 June 2023
Declarations
:
: All study procedures and analyses were reviewed and approved by the University of Washington and University of Mississippi Medical Center Institutional Review Boards (IRB) and carried out in accordance with relevant guidelines and regulations. The RapidPrEP program was a clinical program, and not a research activity. Individuals who received a PrEP prescription in this program were not part of a research study; thus, written informed consent was not required for their participation in the PrEP program. The University of Washington IRB and the University of Mississippi Medical Center IRB waived informed consent for the quantitative analysis of data for this study (which was a medical records review). The quantitative portion of the study included data from individuals who were 16–17 at the time they received PrEP from the Rapid PrEP program. In Mississippi, individuals aged 16–17 can seek sexual health care without parental consent and can participate in sexual health related research without parental consent. Thus, informed consent from a parent and/or legal guardian was waived by the University of Washington IRB and University of Mississippi Medical Center IRB. For the qualitative component of the study, informed consent was obtained from all the individuals who were interviewed. The University of Washington IRB and University of Mississippi Medical Center IRB approved the informed verbal consent procedure. Interviewed participants were all adults (at least 18 years old), so informed consent from a parent and/or legal guardian was not required for study participation.
: n/a
: C.M.K. has received donations of specimen collection kits and reagents from Hologic, Inc. for research studies outside the submitted work. K.V.B is currently employed by Gilead Sciences. Employment began after the completion of client enrollment in RapidPrEP. All other authors declare that they have no competing interests.
